Provided by Tiger Trade Technology Pte. Ltd.

CINGULATE INC.

4.76
+0.01000.21%
Post-market: 4.760.00000.00%19:34 EDT
Volume:52.62K
Turnover:252.32K
Market Cap:69.22M
PE:-1.34
High:4.90
Open:4.79
Low:4.71
Close:4.75
52wk High:11.89
52wk Low:3.16
Shares:14.54M
Float Shares:14.11M
Volume Ratio:0.52
T/O Rate:0.37%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.5600
EPS(LYR):-4.4408
ROE:-198.74%
ROA:-66.94%
PB:2.95
PE(LYR):-1.07

Loading ...

Cingulate Extends Trial Period for Chief Medical Officer Matthew Brams’ Employment Agreement to Dec. 31, 2026

Reuters
·
Yesterday

Cingulate CEO Shane Schaffer to Speak at Indegene Digital Summit on “smart Launch” Commercialization Model

Reuters
·
Sep 17

Cingulate Price Target Cut to $9.00/Share from $10.00 by Roth Capital

Dow Jones
·
Aug 25

Analysts Offer Insights on Healthcare Companies: Eloxx Pharmaceuticals (ELOX), Cingulate Inc (CING) and Agilon Health (AGL)

TIPRANKS
·
Aug 24

Roth MKM Remains a Buy on Cingulate Inc (CING)

TIPRANKS
·
Aug 24

Cingulate price target lowered to $9 from $10 at Roth Capital

TIPRANKS
·
Aug 24

U.S. Research Roundup-Amgen, Analog Devices, Moderna

Reuters
·
Aug 20

Cingulate Inc : Ascendiant Capital Markets Cuts Target Price to $44 from $52

THOMSON REUTERS
·
Aug 20

Maxim Group Keeps Their Buy Rating on Cingulate Inc (CING)

TIPRANKS
·
Aug 14

Cingulate Q2 EPS $(0.45) Beats $(0.63) Estimate

Benzinga Earnings
·
Aug 13

Press Release: Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readiness

Dow Jones
·
Aug 13

Cingulate publishes peer-reviewed data on CTx-1301 pharmacokinetic profile

TIPRANKS
·
Aug 11

Cingulate Publishes Peer-Reviewed Pharmacokinetic Study of ADHD Candidate CTx-1301 in CNS Drugs

Reuters
·
Aug 11

Cingulate Publishes Peer-Reviewed Data Demonstrating CTx-1301’s Differentiated Pharmacokinetic Profile

GlobeNewswire
·
Aug 11

Cingulate Phase 3 ADHD Trial Results for CTx-1301 Published in Journal of Child and Adolescent Psychopharmacology

Reuters
·
Jul 30

Cingulate - Ctx-1301 Shows Statistically Significant Improvements over Placebo in Phase 3 Primary Endpoint

THOMSON REUTERS
·
Jul 30

Cingulate Announces Publication of Phase 3 Adhd Trial Results in Journal of Child and Adolescent Psychopharmacology

THOMSON REUTERS
·
Jul 30

Cingulate Restructures Leadership, Eliminates Chief Legal Officer

TIPRANKS
·
Jul 24

Cingulate Eliminates Chief Legal Officer Role, Nilay Patel to Depart Aug. 3

Reuters
·
Jul 24

Cingulate enhances equity plan and updates board leadership

TIPRANKS
·
Jul 15